BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38102655)

  • 21. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
    Lovegrove CE; Miah S; El-Shater Bosaily A; Bott S; Brown L; Burns-Cox N; Dudderidge T; Freeman A; Henderson A; Hindley R; Kaplan R; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario D; Shergill I; Winkler M; Emberton M; Ahmed HU
    J Urol; 2020 Jan; 203(1):100-107. PubMed ID: 31335254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
    Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.
    Hambrock T; Hoeks C; Hulsbergen-van de Kaa C; Scheenen T; Fütterer J; Bouwense S; van Oort I; Schröder F; Huisman H; Barentsz J
    Eur Urol; 2012 Jan; 61(1):177-84. PubMed ID: 21924545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
    Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT-guided percutaneous biopsy of sclerotic bone lesions: diagnostic outcomes.
    Chang IJ; Ilaslan H; Sundaram M; Schils J; Subhas N
    Skeletal Radiol; 2018 May; 47(5):661-669. PubMed ID: 29218391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.
    Hauth E; Hohmuth H; Cozub-Poetica C; Bernand S; Beer M; Jaeger H
    Br J Radiol; 2015 Oct; 88(1054):20150422. PubMed ID: 26268144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of multiparametric MRI with histopathological grade of peripheral zone prostate carcinoma.
    Singla A; Deep N; Naik S; Mohakud S; Nayak P; Sable M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S569-S576. PubMed ID: 38384020
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    de Jong AC; Smits M; van Riet J; Fütterer JJ; Brabander T; Hamberg P; van Oort IM; de Wit R; Lolkema MP; Mehra N; Segbers M; van der Veldt AAM
    J Nucl Med; 2020 Nov; 61(11):1607-1614. PubMed ID: 32169916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
    Grey ADR; Scott R; Shah B; Acher P; Liyanage S; Pavlou M; Omar R; Chinegwundoh F; Patki P; Shah TT; Hamid S; Ghei M; Gilbert K; Campbell D; Brew-Graves C; Arumainayagam N; Chapman A; McLeavy L; Karatziou A; Alsaadi Z; Collins T; Freeman A; Eldred-Evans D; Bertoncelli-Tanaka M; Tam H; Ramachandran N; Madaan S; Winkler M; Arya M; Emberton M; Ahmed HU
    Lancet Oncol; 2022 Mar; 23(3):428-438. PubMed ID: 35240084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI.
    Elfatairy KK; Filson CP; Sanda MG; Osunkoya AO; Nour SG
    Radiol Imaging Cancer; 2019 Nov; 1(2):e190016. PubMed ID: 33778681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy.
    Rosenkrantz AB; Meng X; Ream JM; Babb JS; Deng FM; Rusinek H; Huang WC; Lepor H; Taneja SS
    J Magn Reson Imaging; 2016 Feb; 43(2):325-32. PubMed ID: 26131965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.
    Sun C; Chatterjee A; Yousuf A; Antic T; Eggener S; Karczmar GS; Oto A
    AJR Am J Roentgenol; 2019 Feb; 212(2):351-356. PubMed ID: 30540213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies.
    Sheikh N; Wei C; Szewczyk-Bieda M; Campbell A; Memon S; Lang S; Nabi G
    World J Urol; 2017 Feb; 35(2):213-220. PubMed ID: 27236302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Objective value on Apparent diffusion coefficient (ADC) map to categorize the intensity of diffusion-weighted imaging (DWI) restriction for prostate cancer detection on multiparametric prostate MRI.
    Mussi TC; Martins T; Tachibana A; Mousessian PN; Baroni RH
    Int Braz J Urol; 2018; 44(5):882-891. PubMed ID: 30044597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized
    Chen HY; Bok RA; Cooperberg MR; Nguyen HG; Shinohara K; Westphalen AC; Wang ZJ; Ohliger MA; Gebrezgiabhier D; Carvajal L; Gordon JW; Larson PEZ; Aggarwal R; Kurhanewicz J; Vigneron DB
    Magn Reson Med; 2022 Dec; 88(6):2609-2620. PubMed ID: 35975978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer?
    Faletti R; Battisti G; Discalzi A; Grognardi ML; Martinello S; Oderda M; Gontero P; Bergamasco L; Cassinis MC; Fonio P
    Abdom Radiol (NY); 2016 May; 41(5):926-33. PubMed ID: 27193791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of cognitive targeting in multiparametric MRI-guided biopsy to diagnose the dominant lesion in prostate cancer.
    Garcia Bennett J; Conejero Olesti A; Hurtado Salom C; Rebenaque E; Parada D; Serrano Alcalá E; Abreu De Con JA
    Radiologia; 2015; 57(5):428-33. PubMed ID: 25464931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies.
    van de Ven WJ; Hulsbergen-van de Kaa CA; Hambrock T; Barentsz JO; Huisman HJ
    Eur Radiol; 2013 May; 23(5):1401-7. PubMed ID: 23138386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
    Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
    Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.